Aitia uses a causal AI-based Gemini Digital Twins platform to model human disease biology for drug discovery and development.
Aitia leverages supercomputing power, a causal AI reverse-engineering forward-simulation (REFS) engine, and extensive patient multiomics and clinical datasets. This technology builds Gemini Digital Twins, which are in silico models of human disease biology. These models are designed to inform every stage of the drug discovery and development pipeline within the biopharma industry. The platform aims to provide a causal understanding of human diseases by revealing molecular interactions that drive them. This understanding identifies novel potential intervention points, which biopharma partners can use to discover, develop, and test precisely targeted drugs. Aitia's approach focuses on generating new biological knowledge to fuel differentiated and novel partnered programs across various diseases with high unmet medical needs, including oncological, neuro-degenerative, immunological, and cardiometabolic conditions.
Platforms: Web
View full Aitia profile on Tools-Radar | Browse Research tools | Alternatives to Aitia
Tools-Radar is a free directory of 10,000+ AI tools — discover, compare, and choose the right AI software for your needs. Visit tools-radar.com